

COORDINATION CHEMISTRY OF IBUPROFEN WITH SELECTED TRANSITION METALS: SYNTHESIS AND CHARACTERIZATION.

A PROJECT REPORT SUBMITTED

BY

ALARAPE QOSHIM

MATRIC NO: ND/23/SLT/PT/0124

**TO THE DEPARTMENT OF SCIENCE LABORATORY TECHNOLOGY ,
INSTITUTE OF BASIC AND APPLIED SCIENCES, KWARA STATE
POLYTECHNIC, ILORIN.**

**IN PARTIAL FUFILMENT OF THE REQUIREMENT FOR THE AWARD OF
NATIONAL DIPLOMA [ND] IN SCIENCE LABRORATORY TECHNOLOGY.**

JUNE, 2025

CERTIFICATION

This is to certify that this project work was carried out by ALARAPE QOSHIM, under the supervision of

MR. OGUNYEMI O.J
PROJECT SUPERVISOR

DATE

MR. LUKMAN Z.A
SLT PT. COORDINATOR

DATE

EXTERNAL EXAMINER

DATE

DEDICATION

My sincere heart of thanks goes to Almighty God for protection and mercy as well as the wisdom granted unto me throughout the National Diploma program

I dedicate this project to my loving and caring parents Elder and Mr. Alarape and to my siblings Byedoh, Hamatulahi and Saadudeen.

ACKNOWLEDGEMENT

My sincere heart of gratitude goes to the almighty Allah, the all in all and most high for the knowledge given to me for the successful completion of my national diploma program.

This project would not have been possible without the cooperation of a very number of people.

My debt in this regard, however, is to my supervisor in person of Mr Ogunyemi O.J whose patience, criticisms and comments extends to fully in time as they did in details. I am extremely grateful and I hope that the final result will not be a disappointment to him.

My immeasurable debt of appreciation also goes to my godly parents, Elder and Mr. Alarape without their long term patience and encouragement through many vicissitudes, this project could never have been completed. I pray you will both live to eat the fruits of your labour.

I also appreciate my siblings and my friends Byedoh, Hamatulahi, Saadudeen, Saoban and Abdulqudus. Thank you all and God bless you all.

ABSTRACT

Some Ibuprofen complexes of Ni[ii], Cu[ii] and Iron[ii] were prepared from the reaction of ibuprofen and metal salts.

The complexes were characterized using physical properties like melting point and solubility test.

LIST OF ABBREVIATONS

Ni	Nickel
Zn	Zinc
Fe	Iron
S	Soluble
Ns	Not Soluble
Ss	Slightly Soluble
Uv	Ultraviolet
IR	InfraRed
G/mol	Gram per mole.

TABLE OF CONTENT

TITLE PAGE	i
CERTIFICATION	ii
DEDICATION	iii
ACKNOWLEDGEMENT	iv
ABSTRACT	v
LIST OF ABBREVIATION	vi
TABLE OF CONTENT	vii
CHAPTER ONE	
1.1 INTRODUCTION	1
1.2 CLINICAL PHARMACOLOGY OF IBUPROFEN	2
1.3 THERAPEUTIC APPLICATION OF IBUPROFEN	3
1.3.1 PATENT DUCTUS ARTEROSUS	4
1.3.2 RHEUMATOID AND OSTERO-ARTHRITIS	4
1.3.3 CYSTIC FIBROSIS	6
1.3.4 ORTHOSTSTIC HYPOTENSION	6
1.3.5 DENTAL PAIN	7
1.3.6 DYSMENORRHEA, FEVER AND HEADACHE	7
1.3.7 PROPHLAXIS OF ALZHEIMER`S DISEASE	8
1.3.8 PARKINSON`S DISEASE	8
1.3.9 BREAST CANCER	8
1.4 ADVERSE REACTIONS	9

1.5	LIGAND AND COMPLEX FORMATION	10
1.6	WHY DRUG-METAL COMPLEX	10
1.7	CHEMISTRY OF TRANSITION METALS USED	11
1.7.1	NICKEL	11
1.7.1.1	COLOUR	12
1.7.1.2	GEOMETRY	12
1.7.1.3	COMPLEXES	13
1.7.2	COPPER	14
1.7.2.1	DEFICIENCY	14
1.7.2.2	TOXICITY	14
1.7.3	IRON	15
1.7.3.1	DEFICIENCY	18
1.8	AIM OF PROJECT	19
CHAPTER TWO		
2.1	MATERIALS AND METHODS	20
2.1.1	APPARATUS	20
2.1.2	REAGENTS	20
2.1.3	MATERIALS	23
2.2	EXPERIMENTAL PROCEDURES	23
2.2.1	IBUPROFEN NI(ii) COMPLEX FORMATION	23
2.2.2	IBUPROFEN CU(ii) COMPLEX FORMATION	24
2.2.3	IBUPROFEN FE(ii) COMPLEX FORMATION	24
2.3	CHARACTERIZATION METHODS	25

2.3.1 SOLUBILITY TESTS	25
2.3.2 MELTING POINT DETERMINATION	25
2.3.3 METHOD	26
CHAPTER THREE	
3.1 RESULTS AND DISCUSSION	27
3.1.1 RESULTS OF SOLUBILITY TEST	27
3.1.2 INTERPRETATION OF SOLUBILITY TEST	28
3.2 RESULTS OF MELTING POINT TEST	28
3.2.1 INTERPRETATION OF MELTING POINT RANGE	28
CHAPTER FOUR	
4.1 CONCLUSION	29
REFERENCES	

CHAPTER ONE

1.1 INTRODUCTION

Ibuprofen was the first member of Propionic acid derivatives introduced in 1969. It is a popular domestic and over the counter analgesic and antipyretic for adults and children. Ibuprofen has been rated as the safest conventional NSAID by spontaneous adverse drug reaction reporting systems in the UK. This project summarizes the main pharmacological effects, therapeutical applications and adverse drug reactions, drug-drug interactions and food drug interactions of ibuprofen that have been reported especially during the last 10 years. Ibuprofen is (2RS)-1[4-(2-methyl propyl) phenyl] propionic indomethacin, are still the most common side effects.¹ acid (BP. 2004). Ibuprofen was the first member of propionic acid derivatives to be introduced in 1969 as a better alternative to Aspirin. Gastric discomfort, nausea and vomiting, though less than aspirin or Ibuprofen is the most commonly used and most frequently prescribed NSAID^{[2][3]} It is a non-selective inhibitor of cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2).^[4] Although its anti inflammatory properties may be weaker than those of some other NSAIDs, it has a prominent analgesic and antipyretic role. Its effects are due to the inhibitory actions on cyclo-oxygenases, which are involved in the synthesis of prostaglandins. Prostaglandins have an important role in the production of pain, inflammation and fever.^[5]

1.2 CLINICAL PHARMACOLOGY OF IBUPROFEN

Ibuprofen is supplied as tablets with a potency of 200 to 800 mg.[6] The usual dose is 400 to 800 mg three times a day.[7] It is almost insoluble in water having pKa of 5.3.[8] It is well absorbed orally; peak serum concentrations are attained in 1 to 2 hours after oral administration. It is rapidly bio-transformed with a serum half life

of 1.8 to 2 hours. The drug is completely eliminated in 24 hours after the last dose and eliminated through metabolism.[9][10]. The drug is more than 99% protein bound, extensively metabolized in the liver and little is excreted unchanged.[11]

Although highly bound to plasma proteins (90-99%),displacement interactions are not clinically significant, hence the dose of oral anti-cogulants and oral hypoglycemic needs not be altered.1 More than 90% of an ingested dose is excreted in the urine as metabolites or their conjugates, the major metabolites are

hydroxylated and carboxylated compounds.[6][12]. Old age has no significant effects on the elimination of ibuprofen.[13]. Renal impairment also has no effect on the kinetics of the drugs, rapid elimination still occur as a consequence of metabolism.[14]. The administration of ibuprofen tablets either under fasting conditions or immediately before meals yield quiet similar serum concentrations-time profile. When it is administered immediately after a meal, there is a reduction in t0he rate of absorption but no appreciable decrease in the extent of absorption.[15]




Figure 1. Structural formula of Ibuprofen

1.3 Therapeutic Application of Ibuprofen

A low dose ibuprofen is as effective as aspirin and paracetamol for the indications normally treated with over the counter medications.[16]. It is widely used as an analgesic, an anti inflammatory and an antipyretic agent.[17-19]. Recemic ibuprofen and S(+) enantiomer are mainly used in the treatment of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, management of spondylitis, osteoarthritis, rheumatoid arthritis and soft tissue disorder.[20]. A number of other actions of NSAIDs can also be attributed to the inhibition of prostaglandins (PGs) or thromboxane synthesis, including alteration in platelet function. (PGI₂ and Thromboxane), prolongation of gestation and labor

(PGE₂, PGF_{2A}), gastrointestinal mucosal damage (PGI₂ and PGE₂), fluid and electrolyte imbalance (renal PGs), premature closure of ductus arteriosus (PGE₂) and bronchial asthma (PGs).[21]. The main therapeutic applications of ibuprofen are as follows:

1.3.1 Patent Ductus arteriosus (PDA)

This is a frequent complication in premature infants. So far, intravenous indomethacin is the standard mode of medical therapy.[22]. However, because of adverse effects of indomethacin, other PG inhibitors such as ibuprofen have been studied for the closure of ductus arteriosus, and results indicated that ibuprofen is as effective as indomethacin.[23]

1.3.2 Rheumatoid and osteo-arthritis (RA and OA)

Ibuprofen is widely used in the management of numerous inflammatory, musculoskeletal and rheumatic disorders, because they are highly effective having minimal toxicities.[24],[25]. Ibuprofen 2400 mg per day resulted in rapid improvement and complete resolution of gouty arthritis within 72 hours.²⁶ In doses of approximately 2400 mg daily, it is equivalent to 4g of aspirin in terms of anti inflammatory effects.[27] Higher doses, 1200 to 1600 mg per day have been compared with a number of NSAIDs and it has been found to be as effective and well tolerated.[28]. Osteoarthritis is very common and treatment involves NSAIDs, particularly ibuprofen.[29],[30] For control of joint symptoms, diclofenac, ibuprofen, tolmetin and naproxen are equally effective.[31].

Roughly 1% of rheumatoid arthritis (RA) patients receiving NSAIDs are prone to develop major GI bleeds.[32]. With ibuprofen, gastric toxicity has been observed in 10 - 32% of patients.[33].

Table 1: Doses of Ibuprofen in adult & Children (34)

Patient	Ibuprofen	Doses
Adult	Analgesia	200-400mg. Every 4-6hrs
	Anti- inflammatory	300 mg, Every 6-8 hrs or 400-800 mg 3-4 times daily.
Children	Antipyretic	5-10 mg/kg. Every 6 hrs (max. 40 mg/kg per day).
	Anti-inflammatory	20-40 mg/kg/day in 3-4 divided dose.

1.3.3 Cystic fibrosis (CF)

High dose ibuprofen therapy has also been shown to be effective in decreasing inflammation, probably by decreasing polymorphonuclear cell influx into the lungs.[34]. The risk of developing GI side effects from high dose ibuprofen therapy is low in patients with CF.[35],[36]

1.3.4 Orthostatic hypotension

Ibuprofen is useful in the treatment of severe orthostatic hypotension as with other NSAIDs.[37]. Toxic effects are unlikely at doses below 100 mg/kg but can be life-threatening or severe above 400 mg/kg.[38].However, large doses do not indicate that the clinical course is likely to be lethal.[39]

1.3.5 Dental pain

Ibuprofen is one of the most effective and widely used NSAID in treatment of dental pain.[40]. Dental practitioners have relied on ibuprofen and other NSAIDs to manage acute and chronic orofacial pain.[41] A dose of 400 mg of ibuprofen provides effective analgesic for the control of postoperative pain after third molar surgery.[42]. A liquid gel preparation of ibuprofen 400mg provides faster relief and superior overall efficacy in post surgical dental pain.[27]

1.3.6 Dysmenorrhea, fever and headache

Non-prescription ibuprofen is useful for managing minor aches and pains, reducing fever and relieving symptoms of dysmenorrhea.[43-45].Dysmenorrhea is the most common menstrual complain.[46].Ibuprofen was superior to placebo for pain relief and menstrual fluid PGF2 alpha suppression.[47]. Cyclooxygenase inhibitors reduce the amount of menstrual prostanoids release, with concomitant reduction in uterine hyper contractility.[48]. Over-the-counter (OTC) ibuprofen preparations are mainly used for acute indications, such as fever or headaches, especially tension type headache.[49-51].It has been reported that the combined use of paracetamol

and ibuprofen reduce fever very rapidly.[52]. Fever almost invariably accompanies uncomplicated falciparum malaria. In a randomized double-‘blind’ study, a single dose of ibuprofen was compared with paracetamol for the treatment of fever $>38.5^{\circ}\text{C}$ due to uncomplicated falciparum malaria. Ibuprofen was significantly more effective than paracetamol in lowering temperatures throughout the first 4-5 hrs after dosing and thus should be considered as an antipyretic agent in the management of uncomplicated falciparum infections, providing there is no contraindication to its use.[53]. Evers *et al.* in 2006, conducted a double blind study to investigate the efficacy of zolmitriptan and ibuprofen in the treatment of migraine in children and adolescents. Pain relief rates after two hours were 28% for placebo, 62% for zolmitriptan and 69% for ibuprofen.[54]

1.3.7 Prophylaxis of Alzheimers disease

The administration of NSAIDs, particularly ibuprofen markedly reduced neurodegeneration.[55],[56]. In some studies, ibuprofen showed superior results compared to placebo in the prophylaxis of Alzheimer’s disease, when given in low doses over a long time. Further studies are needed to confirm the results before ibuprofen can be recommended for this indication.[57]

1.3.8 Parkinson’s disease (PD)

Inflammation and oxidative stress have been implicated as pathogenic mechanisms in PD.[58] Epidemiologic evidence showed that regular use of NSAIDs, particularly non aspirin COX inhibitors such as ibuprofen lower the risk of PD.[59],[60]. It induced apoptosis significantly in

early and late stages, suggesting that these anti-inflammatory agents might inhibit microbial proliferation.⁶¹

1.3.9 Breast cancer

Harris et al. in 1999 conducted a study for utilization of NSAIDs in breast cancer. Breast cancer rate was decreased by approximately 50% with regular ibuprofen intake and 40% with regular aspirin intake. Results suggested that specific NSAIDs may be effective chemopreventive agents against breast cancer.^[62]

1.4 Adverse Reactions

NSAIDs are widely used, frequently taken inappropriately and potentially dangerously.^[63]. Nevertheless, ibuprofen exhibits few adverse effects.^[64] The major adverse reactions include the effects on the gastrointestinal tract (GIT), the kidney and the coagulation system.^[65]. Based on clinical trial data, serious GIT reactions prompting withdrawal of treatment because of hematemesis, peptic ulcer,^[66] and severe gastric pain or vomiting showed an incidence of 1.5% with ibuprofen compared to 1% with placebo and 12.5% with aspirin.^[67] Ibuprofen was a potential cause of GI bleeding,^{[68],[69]} increasing the risk of gastric ulcers and damage, renal failure, epistaxis,^[70-73] apoptosis,^[74] heart failure, hyperkalaemia,^[75] confusion and bronchospasm.^[76] It has been estimated that 1 in 5 chronic users (lasting over a long period of time) of NSAIDs will develop gastric damage which can be silent.^[77] Other adverse effects

of ibuprofen have been reported less frequently. They include thrombocytopenia, rashes, headache,

dizziness, blurred vision and in few cases toxic amblyopia, fluid retention and

ibuprofen.[78] Effects on kidney (as with all NSAIDs) include acute renal failure, interstitial nephritis, and nephritic syndrome, but these very rarely occur.[27]

1.5 LIGAND AND COMPLEX FORMATION

A ligand is an ion or molecule that donates two or more lone pairs of electrons to a metal ion to form coordination or dative bond.

According to Lewis Theory, ligand is a lewis base due to the electrons they donate to empty orbital. They are either anion or polar molecules. Ligands can be classified based on electron pair they donate according to ligand theory. These includes

- i. MONODENTATE LIGAND: they donate one lone pair of electron to neutral metal
e.g $\text{Pt}(\text{Cl})_4$.
- ii. Bidentate LIGAND: they donate two lone pair of electron to neutral metal e.g
 CH_3NH_2
- iii. POLYDENTATE LIGAND: they donate more than two lone pairs of electron i.e the
binding site is beyond one e.g tetraethylenediamine.

1.6 WHY DRUG-METAL COMPLEX

New development in chemotherapy includes the synthesis and characterization of new drug involving metals. Selective novel metal chelators for the treatment of diseases that involves metal or mineral imbalance. Promising research involves some complexes with different metal ions including those of cobalt, copper, titanium, iron, platinum , gold, molybdenum, tin and manganese. Drug metal complexes are used in treatment of metal deficiency diseases.

1.7 CHEMISTRY OF TRANSITION METALS USED

1.7.1 NICKEL

Nickel compounds are chemical compounds containing the element nickel which is a member of the group 10 of the periodic table. Most compounds in the group have an oxidation state of +2. Nickel is classified as a transition metal with nickel(II) having much chemical behavior in common with iron(II) and cobalt(II). Many salts of nickel (II) are isomorphous with salts of magnesium due to the ionic radii of the cations being almost the same. Nickel forms many coordination complexes. Nickel tetracarbonyl was the first pure metal carbonyl produced, and is unusual in its volatility. Metalloproteins containing nickel are found in biological systems. Nickel forms simple binary compounds with non metals including halogens, chalcogenides, and pnictides. Nickel ions can act as a cation in salts with many acids, including common oxoacids. Salts of the hexaaqua ion ($\text{Ni} \cdot 6 \text{H}_2\text{O}^{2+}$) are especially well known. Many double salts containing nickel with another cation are known.

There are organic acid salts. Nickel can be part of a negatively charged ion (anion) making what is called a nickellate. Numerous quaternary compounds (with four elements) of nickel have been studied for superconductivity properties, as nickel is adjacent to copper and iron in the periodic table can form compounds with the same structure as the high-temperature superconductors that are known.

1.7.1.1 Colour

Most of the common [salts](#) of nickel are green due to the presence of hexaaquanickel(II) ion, $\text{Ni}(\text{H}_2\text{O})_6^{2+}$.

1.7.1.2 Geometry

Nickel atoms can connect to surrounding atoms or ligands in a variety of ways. Six coordinated nickel is the most common and is [octahedral](#), but this can be distorted if ligands are not equivalent. For four coordinate nickel arrangements can be square planar, or [tetrahedral](#). Five coordinated nickel is rare.

1.7.1.3 Complexes

Simple complexes of nickel include hexaquonickel(II), yellow [tetracyanonickelate](#) $[\text{Ni}(\text{CN})_4]^{2-}$, red pentacyanonickelate $[\text{Ni}(\text{CN})_5]^{3-}$ only found in solution, $[\text{Ni}(\text{SCN})_4]^{2-}$ and $[\text{Ni}(\text{SCN})_6]^{4-}$. Halo- complexes include $[\text{NiCl}_4]^{2-}$, $[\text{NiF}_4]^{2-}$, $[\text{NiF}_6]^{4-}$, $[\text{NiCl}_2(\text{H}_2\text{O})_4]$ $[\text{Ni}(\text{NH}_3)_4(\text{H}_2\text{O})_2]^{2+}$, $[\text{Ni}(\text{NH}_3)_6]^{2+}$, $[\text{Ni}(\text{en})_3]^{2+}$. [78] Some complexes have fivefold coordination. (tris(N,N-

dimethyl-2-aminoethyl)amine); $\text{P}(\text{o-C}_6\text{H}_4\text{SMe})_3$; $\text{P}(\text{CH}_2\text{CH}_2\text{CH}_2\text{AsMe}_2)_3$ [78] Other ligands for octahedral coordination include [PPh₃](#), [PPh₂Me](#) and [thiourea](#).

Nickel tetrahedral complexes are often bright blue and 20 times or more intensely coloured than the octahedral complexes.[78].The ligands can include selections of neutral [amines](#), [arsines](#), [arsine oxides](#), [phosphines](#) or [phosphine oxides](#) and halogens. Several nickel atoms can cluster together in a compound with other elements to produce nickel cluster complexes. One example where nickel atoms form a square pyramid is a nickel hydride cluster complexed by [triphenyl phosphine](#) ligands and bonding a hydrogen atom on each edge. Another example has a square planar Ni_4H_4 shape in its core.[79] .[Nickel bis\(dimethylglyoximate\)](#), an insoluble red solid is important for [gravimetric analysis](#).

1.7.2 COPPER

Copper along with silver and gold belong to group 1B in the periodic table. These three metals are often referred to as coinage metals. Copper has the electronic configuration of $1\text{S}^22\text{S}^22\text{P}^63\text{S}^23\text{P}^63\text{d}^{10}4\text{S}^1$. Copper is a tough, malleable, ductile metal which resist chemical attack. It has an atomic number of 29, atomic mass of 63.54 and belongs to period 4 and sub-group 1B on the periodic table; it has two natural isotopes with atomic masses between 58 and 68. Copper has a melting point of 1083°C , boiling point of 2590°C and a density of 8.93g/cm^3 .

1.7.2.1 Deficiency

Because of its role in facilitating iron uptake, [copper deficiency](#) can produce [anemia](#)-like symptoms, [neutropenia](#), bone abnormalities, hypopigmentation, impaired growth, increased incidence of infections, osteoporosis, hyperthyroidism, and abnormalities in glucose and cholesterol metabolism. Conversely, [Wilson's disease](#) causes an accumulation of copper in body tissues.

Severe deficiency can be found by testing for low plasma or serum copper levels, low ceruloplasmin, and low red blood cell superoxide dismutase levels; these are not sensitive to marginal copper status. The "cytochrome c oxidase activity of leucocytes and platelets" has been stated as another factor in deficiency, but the results have not been confirmed by replication.[80]

1.7.2.2 TOXICITY

Gram quantities of various copper salts have been taken in suicide attempts and produced acute copper toxicity in humans, possibly due to redox cycling and the generation of [reactive oxygen species](#) that damage [DNA](#). [80][81]. Corresponding amounts of copper salts (30 mg/kg) are toxic in animals.[82] A minimum dietary value for healthy growth in rabbits has been reported to be at least 3 [ppm](#) in the diet.[83] However, higher concentrations of copper (100 ppm, 200 ppm, or 500 ppm) in the diet of rabbits may favorably influence [feed conversion efficiency](#), growth rates, and carcass dressing percentages.[84]

Chronic copper toxicity does not normally occur in humans because of transport systems that regulate absorption and excretion. Autosomal recessive mutations in copper transport proteins can disable these systems, leading to [Wilson's disease](#) with copper accumulation and [cirrhosis](#) of the liver in persons who have inherited two defective genes.[85]

Elevated copper levels have also been linked to worsening symptoms of [Alzheimer's disease](#). [86][87]

1.7.3 IRON

Iron shows the characteristic chemical properties of the [transition metals](#), namely the ability to form variable oxidation states differing by steps of one and a very large coordination and [organometallic chemistry](#): indeed, it was the discovery of an iron compound, [ferrocene](#), that revolutionized the latter field in the 1950s.[88]. Iron is sometimes considered as a prototype for the entire block of transition metals, due to its abundance and the immense role it has played in the technological progress of humanity.[89]. Its 26 electrons are arranged in the [configuration](#) $[\text{Ar}]3d^64s^2$, of which the 3d and 4s electrons are relatively close in energy, and thus a number of electrons can be ionized.[90]

Iron forms compounds mainly in the [oxidation states](#) +2 ([iron\(II\)](#), "ferrous") and +3 ([iron\(III\)](#), "ferric"). Iron also occurs in [higher oxidation states](#), e.g., the purple [potassium ferrate](#) (K_2FeO_4), which contains iron in its +6 oxidation state. The anion $[\text{FeO}_4]^-$ with iron in

its +7 oxidation state, along with an iron(V)-peroxo isomer, has been detected by infrared spectroscopy at 4 K after cocondensation of laser-ablated Fe atoms with a mixture of O₂/Ar.[91] Iron(IV) is a common intermediate in many biochemical oxidation reactions. Numerous [organoiron](#) compounds contain formal oxidation states of +1, 0, −1, or even −2. The oxidation states and other bonding properties are often assessed using the technique of [Mössbauer spectroscopy](#). [90] Many [mixed valence compounds](#) contain both iron(II) and iron(III) centers, such as [magnetite](#) and [Prussian blue](#) (Fe₄(Fe[CN]₆)₃). [89] The latter is used as the traditional "blue" in [blueprints](#). [90] Iron is the first of the transition metals that cannot reach its group oxidation state of +8, although its heavier congeners ruthenium and osmium can, with ruthenium having more difficulty than osmium. [91]. Ruthenium exhibits an aqueous cationic chemistry in its low oxidation states similar to that of iron, but osmium does not, favoring high oxidation states in which it forms anionic complexes. [91]. In the second half of the 3d transition series, vertical similarities down the groups compete with the horizontal similarities of iron with its neighbors in the periodic table, which are also ferromagnetic at [room temperature](#) and share similar chemistry. As such, iron, cobalt, and nickel are sometimes grouped together as the [iron triad](#). [89]

Unlike many other metals, iron does not form amalgams with [mercury](#). As a result, mercury is traded in standardized 76 pound flasks (34 kg) made of iron. [90]

Iron is by far the most reactive element in its group; it is [pyrophoric](#) when finely divided and dissolves easily in dilute acids, giving Fe^{2+} . However, it does not react with concentrated [nitric acid](#) and other oxidizing acids due to the formation of an impervious oxide layer, which can nevertheless react with [\[91\]](#). High-purity iron, called [electrolytic iron](#), is considered to be resistant to rust, due to its oxide layer.

1.7.3.1 DEFICIENCY

Iron deficiency is the most common [nutritional deficiency](#) in the world.[\[92\]\[93\]\[94\]](#) When loss of iron is not adequately compensated by adequate dietary iron intake, a state of [latent iron deficiency](#) occurs, which over time leads to [iron-deficiency anemia](#) if left untreated, which is characterised by an insufficient number of red blood cells and an insufficient amount of hemoglobin.[\[95\]](#) Children, [pre-menopausal](#) women (women of child-bearing age), and people with poor diet are most susceptible to the disease. Most cases of iron-deficiency anemia are mild, but if not treated can cause problems like fast or irregular heartbeat, complications during pregnancy, and delayed growth in infants and children.[\[96\]](#)

The brain is resistant to acute iron deficiency due to the slow transport of iron through the blood brain barrier.[\[97\]](#) Acute fluctuations in iron status (marked by serum ferritin levels) do not reflect brain iron status, but prolonged nutritional iron deficiency is suspected to reduce brain iron concentrations over time.[\[98\]\[99\]](#) In the brain, iron plays a role in oxygen transport, myelin synthesis, mitochondrial respiration, and as a cofactor for neurotransmitter synthesis

and metabolism.[100] Animal models of nutritional iron deficiency report biomolecular changes resembling those seen in Parkinson's and Huntington's disease.[100][102] However, age-related accumulation of iron in the brain has also been linked to the development of Parkinson's.[103]

1.8 AIM OF PROJECT

The aims of this research work are

- (i) To synthesis novel complexes of ibuprofen
- (ii) To characterize the resulting complexes using standard analytical techniques such as solubility, melting point, infrared and ultraviolet .

CHAPTER TWO

2.1 MATERIALS AND METHODS

2.1.1 APPARATUS

The following apparatus were used in the formation of the complexes and further analytical studies were carried out.

APPARATUS	MANUFACTURER
Beakers	Pyrex scientific Ltd. England
Conical Flasks	Simax company Ltd. England
Capillary tube	Silber brand Ltd, England
Dessicator	Moncrief Scientific, England
Electrothermal melting point	Gallenkamp Ltd ,England
Round bottom flasks	Pyrex scientific Ltd, England
Hot plate with magnetic stirrer	Gallenkamp Ltd, England
Measuring cylinder	Technico scientific Ltd, England

Plastic condenser	
Reflux condenser	Moramber (Mbc) Ltd
Test tube	Pyrex scientific Ltd, England
Thermometer	Uniscope scientific Ltd, England
Infrared	Duck V Scientific 500 infrared
Ultraviolet	Jenwoy 6405 UV spectrophotometer.

2.1.2 REAGENTS

The following reagents were collected from chemistry department, Kwara State Polytechnic.

Reagent	Manufacturer
Nickel Sulphate Hexahydrate	
Molecular Formular- $\text{NiSO}_4 \cdot 6\text{H}_2\text{O}$	J.T Barker Chemical C.O Philliburg
Molecular mass =262.71g/mol	
Copper Sulphate	

Molecular formula = CuSO_4 . Eagle Scientific England

Molecular Mass= 159.60g/mol

Iron Sulphate Heptahydrate East Aglia, Chemicals Hadheigh

Molecular Formular= $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$

Molecular Mass =278.02g/mol.

Ethanol East Aglia, Chemicals Hadheigh

Methanol East Aglia, Chemicals Hadheigh

Distilled water

2.1.3 MATERIALS

Ibuprofen

Molecular formular= $\text{C}_{13}\text{H}_{18}\text{O}_2$

Molecular Mass=206.29g/mol

Source BIORAJ Pharmaceuticals, Ilorin.

2.2 EXPERIMENTAL PROCEDURES

All apparatus were cleaned thoroughly before use. The retort stand was set properly and a round bottom flask clamped to it. This was further positioned onto the hotplate with a magnetic

stirrer. A reflux condenser was fixed into the round bottom flask containing the solution and clamped onto the retort stand. Water pipes were connected, one into the inlet and the other into the outlet with both connected to full bucket of water and an empty bucket respectively.

2.2.1 IBUPROFEN Ni (ii) COMPLEX FORMATION

3.52g of ibuprofen was weighed using a digital pocket scale and was then dissolved in 10cm³ of distilled water using a clean dried round bottom flask.

2.38g of NiSO₄.6H₂O was also weighed using a digital pocket scale and was then dissolved in 10cm³ of distilled water in a beaker.

The Nickel solution was added to the ibuprofen solution and shaken vigorously for it to mix well. The magnetic stirrer was placed in the mixture and it was refluxed for 1 hour after which the solution was allowed to cool and a light blue color was observed. The resulting solution was filtered using a filter paper. The precipitate was then washed off with methanol.

The complex obtained was weighed and put in a container which was labeled IBNi(ii) complex.

The weight of the complex obtained was 1.7g of methanol.

2.2.2 IBUPROFEN Cu (ii) COMPLEX FORMATION

3.52g of ibuprofen was weighed using a digital pocket scale and was then dissolved in 10cm³ of distilled water using a clean dried round bottom flask.

1.6g of CuSO₄ was also weighed and was then dissolved in 10cm³ of distilled water in a beaker. The magnetic stirrer was placed in the mixture and it was refluxed for 1 hour after which the solution was allowed to cool and a light green color was observed. The resulting solution was filtered using a filter paper. The precipitate was then washed off with methanol. The complex obtained was weighed and put in a container which was labeled IBCu(ii) complex. The copper solution was added to the ibuprofen solution and shaken vigorously. The weight of the complex obtained was 3.5g.

2.2.3 IBUPROFEN (Fe) FORMATION

3.52g of ibuprofen was weighed using a digital pocket scale and was then dissolved in 10cm³ of distilled water using a clean dried round bottom flask.

3.8g of FeSO₄ was also weighed and was then dissolved in 10cm³ of distilled water in a beaker. The magnetic stirrer was placed in the mixture and it was refluxed for 1 hour after which the solution was allowed to cool and a light brown color was observed. The resulting solution was filtered using a filter paper. The precipitate was then washed off with methanol. The complex obtained was weighed and put in a container which was labeled IBFe(ii) complex. The copper

solution was added to the ibuprofen solution and shaken vigorously. The weight of the complex obtained was 3.2g.

2.3 CHARACTERIZATION METHODS

2.3.1 Solubility Test.

The solubility of the complexes were determined in the following solvents. Ethanol, benzene, methanol, petroleum ether, acetone, distilled water and chloroform

2.3.2 MELTING POINT DETERMINATION

The melting point of the complexes were determined using Gallenkamp melting point apparatus, thermometer and capillary tubes

2.3.3 METHOD

One side of the capillary tubes was sealed and the samples were introduced through the open and to a depth of about 1cm of the tube. The thermometer and the capillary tubes were inserted in the hole provided in the apparatus. The apparatus was switched on and the temperature at which the sample starts to melt and ends was taken as the melting point range of the sample. The melting point temperatures were taken for both the ligand and the complexes.

CHAPTER THREE

3.1 RESULTS AND DISCUSSION

The following are the results of the analysis conducted on some of the complexes formed

3.1.1 RESULTS OF SOLUBILITY TEST

Complex	Ethanol	Benzene	Methanol	Pet. Ether	Acetone	Distilled water	Chloroform
Ibuprofen	NS	NS	NS	NS	NS	S	NS
ligand							
IBNi(ii)	SS	NS	NS	NS	NS	SS	NS
IBCu(ii)	SS	NS	NS	NS	NS	SS	NS
IBFe(ii)	SS	NS	NS	NS	NS	SS	NS

Key S= soluble, SS=slightly soluble NS= not soluble

3.1.2 INTERPRETATION OF SOLUBILITY TEST

From the results obtained from the solubility test, it was evident that all complexes and the ligand were slightly soluble in methanol. Solubility of the ligand and the complexes were poor in ethanol, benzene, petroleum ether, acetone and chloroform.

3.2 RESULTS OF MELTING POINT TEST

COMPLEX	MELTING POINT RANGE
IBUPROFEN LIGAND	190-192
IBNi(ii) COMPLEX	158-160
IBCu(ii) COMPLEX	160-162
IBFe(ii) COMPLEX	211-213

3.2.1 INTERPRETATION OF MELTING POINT RANGE

From the results obtained, it showed that the melting point of the complexes were higher than those of the ligand. This shows that there was coordination.

CHAPTER FOUR

4.1 CONCLUSION

Ibuprofen formed stable complexes with Ni (ii), Cu (ii) and Fe (ii) ions. The solubility test and melting point determination showed that coordination has taken place.

REFERENCES

1. Tripathi KD. Non steroidal anti inflammatory drugs and anti pyretic analgesics
In: Essentials of medical pharmacology. 5th edn., Jaypee Brothers, New Delhi,
2003. p. 176.
2. Abrahm P. KI KD. Nitro-argenine methyl ester, a non selective inhibitor of
nitric oxide synthase reduces ibuprofen-induced gastric mucosal injury in the
rat. Dig Dis 2005;50(9):1632-1640 .
3. Bradbury F. How important is the role of the physician in the correct use of a
drug? An observational cohort study in general practice. Int J Clin Prat 2004;
(144):27-32.
4. Chavez ML, DeKorte CJ. Valdecoxib: a review. Clin Ther 2003 Mar;25(3):817-
851.
5. Wahbi AA, Hassan E, Hamdy D, Khamis E, Barary M. Spectrophotometric
methods for the determination of Ibuprofen in tablets. Pak J Pharm Sci 2005
Oct;18(4):1-6.
6. Roberts LK, Morrow JD. Analgesic antipyretic and anti inflammatory agents
and drugs employed in treatment of gout. In: Hardman JG and Limbird LE
editors. Goodman and Gillman's the pharmacological basis of therapeutics. 10th
ed., McGraw hill, New York, Chicago, 2001.p. 711
7. Ritter JM, Lewis L, Mant TG. Analgesics and the control of pain.In: A text

book of clinical pharmacology. 4th ed., Arnold London, 1999.p. 216

8. Herzfeld CD, Kummel R. Dissociation constant, solubilities and dissolution rate of some selective non steroidal anti inflammatory drugs. *Drug Dev Ind Pharm* 1983;9(5):767-793.

9. Ross JM, DeHoratius J. Non narcotic analgesics. In: DiPalma JR and DiGregorio GJ editors. *Basic pharmacology in medicine* 3rd ed, McGraw hill publishing company New York, 1990. p. 311-316.

10. Antal EJ, Wright CE III, Brown BL, Albert KS, Aman LC, Levin NW. The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites. *J Clin Pharmacol* 1986 Mar;26(3):184-190.

11. Katzung BG, Furst DE. Non steroidal anti inflammatory drugs, disease modifying anti rheumatic drugs, non opioid analgesics, drugs used in gout. In: Katzung BG editor. *Basic and clinical pharmacology*, 7th ed., Appliton and Lang Stamford, Connecticut, 1998. p.586, 1068

12. Olive G. Analgesic/Antipyretic treatment: ibuprofen or acetaminophen? An update. *Therapie* 2006 Mar-Apr;61(2):151-160.

13. Compreton EL, Glass RC, Hird ID. The pharmacokinetic of ibuprofen in elderly and young subjects. 1984 Boots research reports DT 84041.

14. Senekjian HO, Lee C, Kuo TH, Krothapalli R. An absorption and disposition of ibuprofen in hemodialysed uremic patients. *Eur J Rheumatism and*

inflammation 1983; 6(2):155-162.

15. Physician's desk reference. 51st ed., Published by Medical Economic Company, Inc. at Montvale, 1997. p. 1389-1391.

16. Moore N. Forty years of ibuprofen use. *Int J Clin Pract Suppl* 2003 Apr;(135):28-31.

17. Wood DM, Monaghan J, Streeter P, Jones AL, Dargatzis PI. Forty five years of ibuprofen use. 2006 *Critical care*, 10: R 44.

18. Nozu K. Flurbiprofen: highly potent inhibitor of prostaglandin synthesis. *Biochim Biophys Acta* 1978 Jun;529(3):493-496.

19. Adams SS, McCullough KF, Nicholson JS. The pharmacological properties of ibuprofen, an anti-inflammatory, analgesic and antipyretic agent. *Arch Int Pharmacodyn Ther* 1969 Mar;178(1):115-129.

20. Pottast H, Dressman JB, Junginger HE, Midha KK, Oestreicher H, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. *J Pharm Sci* 2005;94(10):2122.

21. Bhattacharya SK, Sen P, Ray A. Central nervous system. In: Das PK editor. *Pharmacology*, 2nd ed., Elsevier, New Delhi, 2003 p. 268

22. Sharma PK, Garg SK, Narang A. Pharmacokinetics of oral ibuprofen in premature infants. *J Clin Pharmacol* 2003 Sep; 43(9):968-973.

23. Kravits DM, Pharm JT. Neonatal therapy. In: Koda-Kimble MA, Young LV,

- Kradjan WA, Guglielmo BJ, Alldredge BK and Corelli RL editors Applied therapeutics: the clinical use of drugs, 8th ed., Lipponcott William and Wilkins A Wolters Kluwer company Philadelphia New York, 2005. p. 94-23.
24. Tan SC, Patel BK, Jackson SH, Swift CG, Hutt AJ. Ibuprofen stereochemistry: double-the-trouble? *Enantiomer* 1999;4(3-4):195-203.
25. Russell TM, Young LY. Arthritic disorders: gout and hyperurecemia. In: Koda-Kimble MA, Young LV, Kradjan WA, Guglielmo BJ, Alldredge BK and Corelli RL editors. Applied therapeutics: the clinical use of drugs. 8th ed., Lipponcott William and Wilkins A Wolters Kluwer company Philadelphia New York, 2005. p. 42-45.
26. Frank WA, Brown MM. Ibuprofen in acute poly articular gout. *Arthritis Rheum.* 1976;19(2):269.
27. Wagner W, Khanna P, Furst DE. Non-steroidal-anti inflammatory drugs, disease modifying anti rheumatic drugs, non opioid analgesics and drugs used in Gout. In: Katzung BG editor. Basic and clinical pharmacology 9th ed., McGraw hill Booston, 2004. p. 585.
28. Gall EP, Caperton EM, McComb JE, Messner R, Multz CV, O'Hanlan M, et al. Clinical comparison of ibuprofen, fenoprofen calcium, naproxen and tolmetin sodium in rheumatoid arthritis. *J Rheumatol* 1982 May-Jun;9(3):402-407.

29. Winstanley P, Walley T. Drug for arthritis. In: Medical pharmacology: a clinical core text for integrated curriculum with self assessment. Churchill Livingstone, Adinburgh, 2002. p. 105-107.
30. Calrk WG, Brater DC, Jhonson AR. Non steroidal anti inflammatory, anti pyretic analgesics. In: Goth's medical pharmacology. 13th ed., Mosby year book. St: Louis Baltimore Booston. 1992.
31. Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases. Br J Rheumatol 1993 Jan;32(1):73-77.
32. Nuki G, Ralston SH, Luqmani R. Diseases of connective tissues, joints and bones. In: Haslett C, Chilvers ER, Hunter JAA and Boon NA editors. Davidson's principles and practice of medicine, 18th ed., Chirchil Livingstone UK, 1999. p. 842-843.
33. Coussement W. Gastrointestinal toxicology: toxicological pathology and sources of intestinal toxicity. In: Niesink RJM, DeVries J and Hollinger MA editors. Toxicology: principles and applications CRC Press, Boca Raton, New York, 1996. p. 655.
34. Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA, Hilliard JB, et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. *J Pharmacol Exp Ther* 2003 Sep;306(3):1086-1091.

35. Mackey JE, Anbar RD. High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report. *BMC Pediatr* 2004 Sep;4:19.
36. Rifai N, Sakamoto M, Law T, Galpchian V, Harris N, Colin AA. Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. *Clin Chem* 1996 Nov;42(11):1812-1816.
37. Zawada ET Jr. Renal consequences of nonsteroidal antiinflammatory drugs. *Postgrad Med* 1982 May;71(5):223-230.
38. Volans G, Hartley V, McCrea S, Monaghan J. Non opioid analgesic poisoning. *Clinical medicine. Clin Med (Northfield IL)* 2003;3(2):119-123.
- An Overview of Clinical Pharmacology... Bushra & Aslam*
39. Seifert SA, Bronstein AC, McGuire T. Massive ibuprofen ingestion with survival. *J Toxicol Clin Toxicol* 2000;38(1):55-57.
40. Bhushan R, Martens J. Resolution of enantiomers of ibuprofen by liquid chromatography: a review. *Biomed Chromatogr* 1998 Nov-Dec;12(6):309-316.
41. Moore T.A, Hersh EV. Celecoxib and refecoxib. The role of Cox-II inhibitors in dental practice. *J Am Dent Assoc* 2011;132(4):451-456.
42. Jones K, Seymour RA, Hawkesford J.E. Synergistic interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the nonsteroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents.

British Journal of Oral and Maxillofacial surgery 1997; 35(3):173-176.

43. Grimes DA, Hubacher D, Lopez LM, Schulz KF. Non steroidal anti inflammatory drugs for heavy bleeding or apin associated with intra uterine device use. *Cochrane Database Syst Rev* 2006;18(4) .

44. Pouresmail Z, Ibrahimzadeh R. Effects of acupuncture and ibuprofen on the severity of primary dysmenorrhea. *J Tradit Chin Med* 2002 Sep;22(3):205-210.

45. Aycock DG. Ibuprofen: a monograph. *Am. Pharm., NS* 1991; 31(1):46-49.

46. Milsom I, Minic M, Dawood MY, Akin MD, Spann J, Niland NF, et al. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. *Clin Ther* 2002 Sep;24(9):1384-1400.

47. Dawood MY, Khan-Dawood FS. Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F₂α in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea. *Am J Obstet Gynecol* 2007 Jan;196(1):35, e1-e5.

48. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. *Obstet Gynecol* 2006 Aug;108(2):428-441.

49. Karttunen P, Saano V, Paronen P, Peura P, Vidgren M. Pharmacokinetics of ibuprofen in man: a single-dose comparison of two over-the-counter, 200 mg

- preparations. *Int J Clin Pharmacol Ther Toxicol* 1990 Jun;28(6):251-255.
50. Diamond S, Freitag FG. The use of ibuprofen plus caffeine to treat tension-type headache. *Curr Pain Headache Rep* 2001 Oct;5(5):472-478.
51. Schoenen J. Treatment of tension headache. *Rev Neurol (Paris)* 2000;156(4) (Suppl 4):S87-S92.
52. Erlewyn-Lajeunesse MD, Coppens K, Hunt LP, Chinnick PJ, Davies P, Higginson IM, et al. Randomised controlled trial of combined paracetamol and ibuprofen for fever. *Arch Dis Child* 2006 May;91(5):414-416.
53. Krishna S, Pukrittayakamee S, Supanaranond W, ter Kuile F, Ruprah M, Sura T, et al. Fever in uncomplicated *Plasmodium falciparum* malaria: randomized double-‘blind’ comparison of ibuprofen and paracetamol treatment. *Trans R Soc Trop Med Hyg* 1995 Sep-Oct;89(5):507-509.
54. Evers S, Rahmann A, Kraemer C, Kurlermann G, Debus O, Husstedt IW, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. *Neurology* 2006 Aug;67(3):497-499.
55. Melton LM, Keith AB, Davis S, Oakley AE, Edwardson JA, Morris CM. Chronic glial activation, neurodegeneration, and APP immunoreactive deposits following acute administration of double-stranded RNA. *Glia* 2003 Oct;44(1):1-12.

56. Casper D, Yaparalvi U, Rempel N, Werner P. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. *Neurosci Lett* 2000 Aug;289(3):201-204.
57. Townsend KP, Praticò D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. *FASEB J* 2005 Oct;19(12):1592-1601.
58. Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. *Mov Disord* 2006 Jul;21(7):964-969.
59. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. *Ann Neurol* 2005 Dec;58(6):963-967.
60. Carrasco E, Casper D, Werner P. Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. *J Neurosci Res* 2005 Jul;81(1):121-131.
61. Elsisi NS, Darling-Reed S, Lee EY, Oriaku ET, Soliman KF. Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. *Neurosci Lett* 2005 Feb;375(2):91-96.
62. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. *Oncol Rep* 1999 Jan-Feb;6(1):71-73.

63. Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. *J Rheumatol* 2005 Nov;32(11):2218-2224.
64. Bateman DN. NSAIDs: time to re-evaluate gut toxicity. *Lancet* 1994 Apr;343(8905):1051-1052.
65. Rocca GD, Chiarandini P, Pietropaoli P. Analgesia in PACU: nonsteroidal anti-inflammatory drugs. *Curr Drug Targets* 2005 Nov;6(7):781-787.
66. Tsokos M and Schmoldt A. Contribution of non steroidal anti inflammatory drugs to death associated with peptic ulcer disease:a prospective toxicological analysis of autopsy blood samples. *Arch Pathol gLab Med* 2001; 125 (12):1572-1574.
67. Dollery C. Therapeutic drugs 2nd ed., vol. 1, Churchill Livingstone Edinburgh London, 1999. p. 12.
68. Wolfe MM, Lichenstein DR, Signh G. Gastrointestinal toxicity of non steroidal anti inflammatory drugs. *M. Engl.J.Med* 1999; 340:1888(24)-1899.
69. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. *Chest* 1999 Apr;115(4):1053-1058.

70. Gambero A, Becker TL, Zago AS, de Oliveira AF, Pedrazzoli J Jr. Comparative study of anti-inflammatory and ulcerogenic activities of different cyclooxygenase inhibitors. *Inflammopharmacology* 2005;13(5-6):441-454.
71. Fulcher EM, Soto CD, Fulcher RM. Medications for disorders of the musculoskeletal system. In: Principles and applications. A work text for allied health professionals. Saunders, an imprint of Elsevier Science Philadelphia, 2003. p. 510.
72. Kennedy MJ. Inflammation and cystic fibrosis pulmonary disease. *Pharmacotherapy* 2001 May;21(5):593-603.
73. Kovesi TA, Swartz R, MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. *N Engl J Med* 1998 Jan;338(1):65-66.
74. Durkin E, Moran AP, Hanson PJ. Apoptosis induction in gastric mucous cells in vitro: lesser potency of *Helicobacter pylori* than *Escherichia coli* lipopolysaccharide, but positive interaction with ibuprofen. *J Endotoxin Res* 2006;12(1):47-56.
75. Vale JA, Meredith TJ. Acute poisoning due to non-steroidal anti-inflammatory drugs. Clinical features and management. *Med Toxicol* 1986 Jan-Feb;1(1):12-31.
76. Rossi S. (2004). Australian medicine hand book ISBN 0-9578521-4-2.
77. Rang HP, Dale MM, Ritter JM. Anti-inflammatory and immune suppressant

drugs. In: Pharmacology. 5th ed., Churchill Livingstone Edinburgh London, 1999. p. 248.

78. Shoshani, Manar M.; Beck, Robert; Wang, Xiaoping; McLaughlin, Matthew J.; Johnson, Samuel A. (15 November 2017). "Synthesis of Surface-Analogue Square-Planar Tetranuclear Nickel Hydride Clusters and Bonding to μ_4 -NR, -O and -BH Ligands". *Inorganic Chemistry*. **57** (5):

Cotton and Wilkinson (1966). *Advanced Inorganic Chemistry: A Comprehensive Treatise*. John Wiley & Sons. pp. 878–893.

80 Bonham, Maxine; O'Connor, Jacqueline M.; Hannigan, Bernadette M.; Strain, J.J. (2002). "The immune system as a physiological indicator of marginal copper status?". *British Journal of Nutrition*. **87** (5): 393–403.

81 Li, Yunbo; Trush, Michael; Yager, James (1994). "DNA damage caused by reactive oxygen species originating from a copper-dependent oxidation of the 2-hydroxy catechol of estradiol". *Carcinogenesis*. **15** (7): 1421–1427

82 Gordon, Starkebaum; John, M. Harlan (April 1986). "Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine". *J. Clin. Invest.* **77** (4): 1370–6.

83 Cornell University. Retrieved 10 July 2008.

84_Hunt, Charles E. & William W. Carlton (1965). "Cardiovascular Lesions Associated with Experimental Copper Deficiency in the Rabbit". *Journal of Nutrition*. **87** (4): 385–394.

85 Ayyat M.S.; Marai I.F.M.; Alazab A.M. (1995). "Copper-Protein Nutrition of New Zealand White Rabbits under Egyptian Conditions". *World Rabbit Science*. **3** (3): 113–118

86_Brewer GJ (March 2012). "Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease". *BioFactors* (Review). **38** (2) 107-113

87 Copper: Alzheimer's Disease". *Examine.com*. Retrieved 21 June 2015.

88 Lu, Jun-Bo; Jian, Jiwen; Huang, Wei; Lin, Hailu; Li, Jun; Zhou, Mingfei (16 November 2016). "Experimental and theoretical identification of the Fe(VII) oxidation state in FeO_4^- ". *Phys. Chem. Chem. Phys.* **18** (45): 31125–31131.

89 Nam, Wonwoo (2007). "[High-Valent Iron\(IV\)–Oxo Complexes of Heme and Non-Heme Ligands in Oxygenation Reactions](#)". *Accounts of Chemical Research*. **40** (7): 522–531.

90 Holleman, Arnold F.; Wiberg, Egon; Wiberg, Nils (1985). "Iron". *Lehrbuch der Anorganischen Chemie (in German) (91–100 ed.)*. Walter de Gruyter. pp. 1125–46

91[Greenwood & Earnshaw 1997](#), pp. 1075–79.

92 Centers for Disease Control and Prevention (2002). "[Iron deficiency – United States, 1999–2000](#)". *MMWR*. **51** (40): 897–99.

- 93 Hider, Robert C.; Kong, Xiaole (2013). "Chapter 8. Iron: Effect of Overload and Deficiency". In Astrid Sigel, Helmut Sigel and Roland K.O. Sigel (ed.). *Interrelations between Essential Metal Ions and Human Diseases. Metal Ions in Life Sciences. Vol. 13.* Springer. pp. 229–94.
- 94 Dlouhy, Adrienne C.; Outten, Caryn E. (2013). "The Iron Metallome in Eukaryotic Organisms". In Banci, Lucia (ed.). *Metallomics and the Cell. Metal Ions in Life Sciences. Vol. 12.* Springer. pp. 241–78
- 95 CDC Centers for Disease Control and Prevention (3 April 1998). ["Recommendations to Prevent and Control Iron Deficiency in the United States"](#). *Morbidity and Mortality Weekly Report*. **47** (RR3): 1. Retrieved 12 August 2014.
- 96 Centers for Disease Control and Prevention. ["Iron and Iron Deficiency"](#).
- 97 Youdim, M. B.; Ben-Shachar, D.; Yehuda, S. (September 1989). ["Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior"](#). *The American Journal of Clinical Nutrition*. **50** (3 Suppl): 607–615, discussion 615–617. .
- 98 Erikson, K. M.; Pinero, D. J.; Connor, J. R.; Beard, J. L. (October 1997). ["Regional brain iron, ferritin and transferrin concentrations during iron deficiency and iron repletion in developing rats"](#). *The Journal of Nutrition*. **127** (10): 2030–2038.
- 99 Unger, Erica L.; Bianco, Laura E.; Jones, Byron C.; Allen, Richard P.; Earley, Christopher J. (November 2014). ["Low brain iron effects and reversibility on striatal dopamine dynamics"](#). *Experimental Neurology*. **261**: 462–468. Ward, Roberta J.;

Zucca, Fabio A.; Duyn, Jeff H.; Crichton, Robert R.; Zecca, Luigi (October 2014). ["The role of iron in brain ageing and neurodegenerative disorders"](#). *The Lancet. Neurology*. **13** (10): 1045–1060.

100 [^](#) Pino, Jessica M. V.; da Luz, Marcio H. M.; Antunes, Hanna K. M.; Giampá, Sara Q. de Campos; Martins, Vilma R.; Lee, Kil S. (17 May 2017). ["Iron-Restricted Diet Affects Brain Ferritin Levels, Dopamine Metabolism and Cellular Prion Protein in a Region-Specific Manner"](#). *Frontiers in Molecular Neuroscience*. **10**: 145.

101 [^](#) Beard, John; Erikson, Keith M.; Jones, Byron C. (1 April 2003). ["Neonatal Iron Deficiency Results in Irreversible Changes in Dopamine Function in Rats"](#). *The Journal of Nutrition*. **133** (4): 1174–1179.